<p>MiMedx Group（納斯達克代碼：MDXG - 獲取免費報告）在週六發佈的一份報告中被華爾街 Zen 的股票研究人員從 “強力買入” 評級下調至 “買入” 評級。</p>
<p>MDXG 一直是其他多份報告的主題。Weiss Ratings 在 12 月 29 日的研究報告中重申了對 MiMedx Group 股票的 “持有（c）” 評級。Cantor Fitzgerald 在 2 月 17 日的報告中將 MiMedx Group 的目標價格從 12.00 美元下調至 8.00 美元，並對該股票設定了 “增持” 評級。花旗集團在週一的研究報告中開始覆蓋 MiMedx Group，並對該股票給予了 “市場表現優於大盤” 的評級。Citizens Jmp 在 2 月 23 日的報告中開始覆蓋 MiMedx Group，設定了 “市場表現優於大盤” 的評級和 10.00 美元的價格目標。最後，瑞銀集團在週一的研究報告中設定了 MiMedx Group 的 10.00 美元價格目標。五位投資分析師對該股票給予了買入評級，一位給予了持有評級。根據 MarketBeat 的數據，MiMedx Group 的平均評級為 “適度買入”，共識目標價格為 9.60 美元。</p>
<p><strong>獲取我們關於 MiMedx Group 的最新研究報告</strong></p>
<h2>MiMedx Group 股票下跌 1.0%</h2>
<p>週五，MiMedx Group 股票開盤價為 4.89 美元。該公司的市值為 7.2422 億美元，市盈率為 15.28，貝塔值為 1.59。該股票的 50 日簡單移動平均為 5.70 美元，200 日簡單移動平均為 6.58 美元。MiMedx Group 的 52 周低點為 4.78 美元，52 周高點為 8.46 美元。該公司的債務與股本比率為 0.07，流動比率為 4.41，速動比率為 3.95。</p>
<p>MiMedx Group（納斯達克代碼：MDXG - 獲取免費報告）最後一次發佈季度財報是在 2 月 25 日，報告顯示該季度每股收益（EPS）為 0.14 美元，超出分析師共識預期的 0.09 美元，超出幅度為 0.05 美元。該公司在該季度的收入為 1.181 億美元，而分析師的預期為 1.0678 億美元。MiMedx Group 的淨利潤率為 11.60%，股本回報率為 30.61%。平均而言，股票研究分析師預計 MiMedx Group 在當前財年將發佈 0.3 美元的每股收益。</p>
<h2>對 MiMedx Group 的對沖基金看法</h2>
<p>最近，一些對沖基金對該公司的持倉進行了調整。First Light Asset Management LLC 在第三季度將其在 MiMedx Group 的持股增加了 89.5%。First Light Asset Management LLC 現在擁有該公司 3,652,952 股股票，價值 25,498,000 美元，此前在此期間又收購了 1,725,458 股。Nantahala Capital Management LLC 在第三季度獲得了 MiMedx Group 的新頭寸，價值約為 10,237,000 美元。Marshall Wace LLP 在第四季度將其在 MiMedx Group 的持股增加了 864.9%。Marshall Wace LLP 現在擁有該公司 1,381,288 股股票，價值 9,351,000 美元，此前在此期間又購買了 1,238,132 股。Hillsdale Investment Management Inc.在第四季度獲得了 MiMedx Group 的新股份，價值約為 7,134,000 美元。最後，Disciplined Growth Investors Inc. MN 在第三季度將其在 MiMedx Group 的持股增加了 283.0%。Disciplined Growth Investors Inc. MN 現在擁有該公司 1,383,451 股股票，價值 9,656,000 美元，此前在上個季度又購買了 1,022,202 股。機構投資者和對沖基金持有該公司 79.15% 的股票。</p>
<h2>關於 MiMedx Group</h2>
<p>（獲取免費報告）</p>
<p>MiMedx Group, Inc 是一家生物製藥公司，專注於開發、製造和營銷源自人類胎盤組織的再生生物材料產品。該公司的核心使命是利用羊膜和絨毛膜中的細胞外基質和生長因子來支持傷口癒合和外科應用。MiMedx 的產品線利用專有的淨化工藝，旨在保留原生組織特性，同時確保無菌和安全。</p>
<p>MiMedx 的主要產品包括以 EpiFix®和 AmnioFix®等名稱品牌的羊膜/絨毛膜同種異體移植物，適用於急性和慢性傷口的治療，包括糖尿病足潰瘍、靜脈性腿部潰瘍和手術部位修復。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票比 MiMedx Group 更好</li>
<li>用這 4 個簡單步驟 “防止美聯儲影響” 你的銀行賬户</li>
<li>有史以來最大的 IPO……向普通人開放</li>
<li>銀價記錄很好，月收入更好</li>
<li>閲讀此文，否則將永遠後悔</li>
<li>賣這個，買那個</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 MiMedx Group 嗎？</h2>
<p>在你考慮 MiMedx Group 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 MiMedx Group 並不在名單上。</p>
<p>雖然 MiMedx Group 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MDXG

<p>華爾街禪將 MiMedx Group（NASDAQ:MDXG）的評級從 “強力買入” 下調至 “買入”。其他分析師也給出了混合評級，Weiss Ratings 維持 “持有（c）” 評級，而 Cantor Fitzgerald 將目標價格從 12.00 美元下調至 8.00 美元。MiMedx Group 的股票開盤價為 4.89 美元，市值為 7.2422 億美元。該公司報告每股收益為 0.14 美元，超出預期，營收為 1.181 億美元。機構投資者持有該股票的 79.15%，該公司專注於用於傷口癒合的再生生物材料產品</p>

<p>MiMedx Group (NASDAQ:MDXG - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report released on Saturday.</p>
<div class="lb-trans"><p>MiMedx Group（納斯達克代碼：MDXG - 獲取免費報告）在週六發佈的一份報告中被華爾街 Zen 的股票研究人員從 “強力買入” 評級下調至 “買入” 評級。</p>
</div><p>MDXG has been the topic of a number of other reports. Weiss Ratings reiterated a &#34;hold (c)&#34; rating on shares of MiMedx Group in a research note on Monday, December 29th. Cantor Fitzgerald lowered their target price on MiMedx Group from $12.00 to $8.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday, February 17th. Citigroup started coverage on MiMedx Group in a research report on Monday. They issued a &#34;market outperform&#34; rating on the stock. Citizens Jmp started coverage on MiMedx Group in a report on Monday, February 23rd. They set a &#34;market outperform&#34; rating and a $10.00 price target for the company. Finally, UBS Group set a $10.00 price objective on MiMedx Group in a research report on Monday. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, MiMedx Group has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $9.60.</p>
<div class="lb-trans"><p>MDXG 一直是其他多份報告的主題。Weiss Ratings 在 12 月 29 日的研究報告中重申了對 MiMedx Group 股票的 “持有（c）” 評級。Cantor Fitzgerald 在 2 月 17 日的報告中將 MiMedx Group 的目標價格從 12.00 美元下調至 8.00 美元，並對該股票設定了 “增持” 評級。花旗集團在週一的研究報告中開始覆蓋 MiMedx Group，並對該股票給予了 “市場表現優於大盤” 的評級。Citizens Jmp 在 2 月 23 日的報告中開始覆蓋 MiMedx Group，設定了 “市場表現優於大盤” 的評級和 10.00 美元的價格目標。最後，瑞銀集團在週一的研究報告中設定了 MiMedx Group 的 10.00 美元價格目標。五位投資分析師對該股票給予了買入評級，一位給予了持有評級。根據 MarketBeat 的數據，MiMedx Group 的平均評級為 “適度買入”，共識目標價格為 9.60 美元。</p>
</div><p><strong>Get Our Latest Research Report on MiMedx Group</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 MiMedx Group 的最新研究報告</strong></p>
</div><h2>MiMedx Group Stock Down 1.0%</h2>
<div class="lb-trans"><h2>MiMedx Group 股票下跌 1.0%</h2>
</div><p>Shares of MiMedx Group stock opened at $4.89 on Friday. The firm has a market cap of $724.22 million, a price-to-earnings ratio of 15.28 and a beta of 1.59. The stock has a 50-day simple moving average of $5.70 and a 200-day simple moving average of $6.58. MiMedx Group has a 52-week low of $4.78 and a 52-week high of $8.46. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.41 and a quick ratio of 3.95.</p>
<div class="lb-trans"><p>週五，MiMedx Group 股票開盤價為 4.89 美元。該公司的市值為 7.2422 億美元，市盈率為 15.28，貝塔值為 1.59。該股票的 50 日簡單移動平均為 5.70 美元，200 日簡單移動平均為 6.58 美元。MiMedx Group 的 52 周低點為 4.78 美元，52 周高點為 8.46 美元。該公司的債務與股本比率為 0.07，流動比率為 4.41，速動比率為 3.95。</p>
</div><p>MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.05. The firm had revenue of $118.10 million during the quarter, compared to analysts' expectations of $106.78 million. MiMedx Group had a net margin of 11.60% and a return on equity of 30.61%. On average, equities research analysts expect that MiMedx Group will post 0.3 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>MiMedx Group（納斯達克代碼：MDXG - 獲取免費報告）最後一次發佈季度財報是在 2 月 25 日，報告顯示該季度每股收益（EPS）為 0.14 美元，超出分析師共識預期的 0.09 美元，超出幅度為 0.05 美元。該公司在該季度的收入為 1.181 億美元，而分析師的預期為 1.0678 億美元。MiMedx Group 的淨利潤率為 11.60%，股本回報率為 30.61%。平均而言，股票研究分析師預計 MiMedx Group 在當前財年將發佈 0.3 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On MiMedx Group</h2>
<div class="lb-trans"><h2>對 MiMedx Group 的對沖基金看法</h2>
</div><p>A number of hedge funds have recently made changes to their positions in the business. First Light Asset Management LLC lifted its holdings in shares of MiMedx Group by 89.5% during the 3rd quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company's stock worth $25,498,000 after acquiring an additional 1,725,458 shares during the period. Nantahala Capital Management LLC acquired a new position in MiMedx Group in the third quarter worth about $10,237,000. Marshall Wace LLP lifted its stake in MiMedx Group by 864.9% during the fourth quarter. Marshall Wace LLP now owns 1,381,288 shares of the company's stock worth $9,351,000 after purchasing an additional 1,238,132 shares during the period. Hillsdale Investment Management Inc. acquired a new stake in MiMedx Group during the fourth quarter valued at approximately $7,134,000. Finally, Disciplined Growth Investors Inc. MN boosted its holdings in MiMedx Group by 283.0% during the third quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company's stock valued at $9,656,000 after purchasing an additional 1,022,202 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company's stock.</p>
<div class="lb-trans"><p>最近，一些對沖基金對該公司的持倉進行了調整。First Light Asset Management LLC 在第三季度將其在 MiMedx Group 的持股增加了 89.5%。First Light Asset Management LLC 現在擁有該公司 3,652,952 股股票，價值 25,498,000 美元，此前在此期間又收購了 1,725,458 股。Nantahala Capital Management LLC 在第三季度獲得了 MiMedx Group 的新頭寸，價值約為 10,237,000 美元。Marshall Wace LLP 在第四季度將其在 MiMedx Group 的持股增加了 864.9%。Marshall Wace LLP 現在擁有該公司 1,381,288 股股票，價值 9,351,000 美元，此前在此期間又購買了 1,238,132 股。Hillsdale Investment Management Inc.在第四季度獲得了 MiMedx Group 的新股份，價值約為 7,134,000 美元。最後，Disciplined Growth Investors Inc. MN 在第三季度將其在 MiMedx Group 的持股增加了 283.0%。Disciplined Growth Investors Inc. MN 現在擁有該公司 1,383,451 股股票，價值 9,656,000 美元，此前在上個季度又購買了 1,022,202 股。機構投資者和對沖基金持有該公司 79.15% 的股票。</p>
</div><h2>About MiMedx Group</h2>
<div class="lb-trans"><h2>關於 MiMedx Group</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.</p>
<div class="lb-trans"><p>MiMedx Group, Inc 是一家生物製藥公司，專注於開發、製造和營銷源自人類胎盤組織的再生生物材料產品。該公司的核心使命是利用羊膜和絨毛膜中的細胞外基質和生長因子來支持傷口癒合和外科應用。MiMedx 的產品線利用專有的淨化工藝，旨在保留原生組織特性，同時確保無菌和安全。</p>
</div><p>MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.</p>
<div class="lb-trans"><p>MiMedx 的主要產品包括以 EpiFix®和 AmnioFix®等名稱品牌的羊膜/絨毛膜同種異體移植物，適用於急性和慢性傷口的治療，包括糖尿病足潰瘍、靜脈性腿部潰瘍和手術部位修復。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than MiMedx Group</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>The Biggest IPO Ever… Open to Everyday Folks</li>
<li>Silver records prices are great. Monthly income is better</li>
<li>Read this or regret it forever</li>
<li>Sell this, buy that</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比 MiMedx Group 更好</li>
<li>用這 4 個簡單步驟 “防止美聯儲影響” 你的銀行賬户</li>
<li>有史以來最大的 IPO……向普通人開放</li>
<li>銀價記錄很好，月收入更好</li>
<li>閲讀此文，否則將永遠後悔</li>
<li>賣這個，買那個</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=MDXG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MiMedx Group Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 MiMedx Group 嗎？</h2>
</div><p>Before you consider MiMedx Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 MiMedx Group 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 MiMedx Group 並不在名單上。</p>
</div><p>While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MiMedx Group 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

MiMedx 集團（NASDAQ:MDXG）被華爾街 Zen 下調評級至買入